瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽

瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽

ID:8229776

大?。?.75 MB

頁(yè)數(shù):110頁(yè)

時(shí)間:2018-03-11

瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽_第1頁(yè)
瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽_第2頁(yè)
瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽_第3頁(yè)
瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽_第4頁(yè)
瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽_第5頁(yè)
資源描述:

《瑞信-美股-制藥業(yè)-美國(guó)制藥業(yè)預(yù)覽》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。

1、USPharmaceuticalsPolitics,PipelineandNewProductsinFocus;PreferMRK,AGNandJNJforLarge-Caps;ALKS,AIMTandMYOKinSMIDBottomLine:Inthefinalquarterof2017,weanticipateinvestorswillcontinuetokeepaneyeonmacroOctober2017issuessuchasU.S.drugpricingandpotentialU.S.corporatetaxreform,althou

2、ghasignificantamountofproductnewsshouldalsoimpacthowinvestorsviewthevariousnames.Overall,webelievesentimentonthegroupremainsrelativelyrobustwithnoiseonthedrugpricingsidefarbelowwhatithasbeenandRESEARCHANALYSTSinvestorsstillcautiouslyoptimisticonthepossibilityofcorporatetaxref

3、ormcomingthroughin2018.VamilDivan,MDDependingonhowtheseissuesplayout,itcouldalsoleadtoincreasedexcitementaroundpotential(212)538-5394businessdevelopmentandM&Ainthesector,aswebelievemostofourlargecapcompaniesarestillvamil.divan@credit-suisse.comwaitingforfurtherclarityonthesei

4、ssuesbeforeannouncingtransformativedeals.Inadditiontoprovidingnewgrowthdriverstoourlargecapcompanies,businessdevelopmenteffortswillalsolikelyboostinterestinourSMIDcapnamesthatcouldbepotentialtargets.OntheproductsidewehaveimportantdataMichaelV.Morabito,Ph.D.releasesexpectedbyy

5、earendinlargemarketssuchasoncology/immuno-oncology,rheumatoidarthritis(212)325-7298andpsoriasis,aswellasinmorespecializedmarketssuchaspeanutallergy.michael.morabito@credit-suisse.comPreferMRK,AGNandJNJinlargecap.WeviewMRKasourTopPickinouruniverseasweexpectKeytrudatobeatexpect

6、ationsanddriveupsidethroughthecourseoftheyear,althoughtheirrecoveryfromtherecentcyber-attackbearswatching.SentimentaroundAGNremainssplitbutweassumefurtherBarbaraKoteistabilityinthebasebusinessandimprovingcashflowsandearningsqualityshouldallowforfocustoshift(212)538-8119totheo

7、ptionalityinthepipelinelaterintheyear,especiallyoncewehavesomeclarityontheRestasisbarbara.kotei@credit-suisse.compatentsituation.WeseeJNJ’sPharmaceuticalsSegmentdrivingupsideforthecompany,specificallyproductssuchasXarelto,Darzalex,Imbruvica,andtheschizophreniafranchise.DuaaMo

8、hamedSeeopportunitiesinSMIDcap,ledbyALKS,AIMTandMYOK.Vivitrolremains

當(dāng)前文檔最多預(yù)覽五頁(yè),下載文檔查看全文

此文檔下載收益歸作者所有

當(dāng)前文檔最多預(yù)覽五頁(yè),下載文檔查看全文
溫馨提示:
1. 部分包含數(shù)學(xué)公式或PPT動(dòng)畫的文件,查看預(yù)覽時(shí)可能會(huì)顯示錯(cuò)亂或異常,文件下載后無此問題,請(qǐng)放心下載。
2. 本文檔由用戶上傳,版權(quán)歸屬用戶,天天文庫(kù)負(fù)責(zé)整理代發(fā)布。如果您對(duì)本文檔版權(quán)有爭(zhēng)議請(qǐng)及時(shí)聯(lián)系客服。
3. 下載前請(qǐng)仔細(xì)閱讀文檔內(nèi)容,確認(rèn)文檔內(nèi)容符合您的需求后進(jìn)行下載,若出現(xiàn)內(nèi)容與標(biāo)題不符可向本站投訴處理。
4. 下載文檔時(shí)可能由于網(wǎng)絡(luò)波動(dòng)等原因無法下載或下載錯(cuò)誤,付費(fèi)完成后未能成功下載的用戶請(qǐng)聯(lián)系客服處理。